A close structural analog of 2-methyl-6-(phenylethynyl)pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators

被引:100
作者
Rodriguez, AL
Nong, Y
Sekaran, NK
Alagille, D
Tamagnan, GD
Conn, PJ
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Program Translat Neuropharmacol, Nashville, TN 37232 USA
[3] Inst Neurodegenerat Disorders, New Haven, CT USA
关键词
D O I
10.1124/mol.105.016139
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The metabotropic glutamate receptor subtype 5 (mGlu5) activates calcium mobilization via binding of glutamate, the major excitatory neurotransmitter in the central nervous system. Allosteric modulation of the receptor has recently emerged as a promising alternative method of regulation to traditional regulation through orthosteric ligands. We now report three novel compounds that bind to the allosteric 2-methyl-6-(phenylethynyl)pyridine (MPEP) site on mGlu5 but have only partial inhibition or no functional effects on the mGlu5 response. Two of these compounds, 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP) and 2-(2-(5-bromopyridin-3-yl)ethynyl)5-methylpyridine (Br-5MPEPy), act as partial antagonists of mGlu5 in that they only partially inhibit the response of this receptor to glutamate. The third compound, 5-methyl-6-(phenylethynyl)pyridine (5MPEP), acts as a neutral allosteric site ligand that binds to the MPEP site and has no effects alone. However, 5MPEP blocks the effects of both the allosteric antagonist MPEP and potentiators 3,3'-difluorobenzaldazine and 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB). This compound also blocks depolarization effects of both MPEP and CDPPB in neurons in the subthalamic nucleus. These novel compounds provide valuable new insight into the pharmacology of allosteric sites on G protein-coupled receptors and provide valuable new tools for determining the effects of allosteric site ligands in native systems.
引用
收藏
页码:1793 / 1802
页数:10
相关论文
共 40 条
  • [31] Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice
    Du, Yonglei
    Gao, Feng
    Sun, Hongwei
    Wu, Chenglin
    Zhu, Guoqi
    Zhu, Manzhou
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 261
  • [32] Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo [1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5
    Felts, Andrew S.
    Rodriguez, Alice L.
    Morrison, Ryan D.
    Bollinger, Katrina A.
    Venable, Daryl F.
    Blobaum, Anna L.
    Byers, Frank W.
    Gray, Analisa Thompson
    Daniels, J. Scott
    Niswender, Colleen M.
    Jones, Carrie K.
    Conn, P. Jeffrey
    Lindsley, Craig W.
    Emmitte, Kyle A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (21) : 4858 - 4866
  • [33] Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation
    Felts, Andrew S.
    Rodriguez, Alice L.
    Blobaum, Anna L.
    Morrison, Ryan D.
    Bates, Brittney S.
    Gray, Analisa Thompson
    Rook, Jerri M.
    Tantawy, Mohammed N.
    Byers, Frank W.
    Chang, Sichen
    Venable, Daryl F.
    Luscombe, Vincent B.
    Tamagnan, Gilles D.
    Niswender, Colleen M.
    Daniels, J. Scott
    Jones, Carrie K.
    Conn, P. Jeffrey
    Lindsley, Craig W.
    Emmitte, Kyle A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (12) : 5072 - 5085
  • [34] Discovery of Novel Central Nervous System Penetrant Metabotropic Glutamate Receptor Subtype 2 (mGlu2) Negative Allosteric Modulators (NAMs) Based on Functionalized Pyrazolo[1,5-a]pyrimidine-5-carboxamide and Thieno[3,2-b]pyridine-5-carboxamide Cores
    Childress, Elizabeth S.
    Wieting, Joshua M.
    Felts, Andrew S.
    Breiner, Megan M.
    Long, Madeline F.
    Luscombe, Vincent B.
    Rodriguez, Alice L.
    Cho, Hyekyung P.
    Blobaum, Anna L.
    Niswender, Colleen M.
    Emmitte, Kyle A.
    Conn, P. Jeffrey
    Lindsley, Craig W.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (01) : 378 - 384
  • [35] Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents:: Detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]
    Satow, Akio
    Maehara, Shunsuke
    Ise, Satoko
    Hikichi, Hirohiko
    Fukushima, Miyuki
    Suzuki, Gentaroh
    Kimura, Toshifumi
    Tanaka, Takeshi
    Ito, Satoru
    Kawamoto, Hiroshi
    Ohta, Hisashi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 326 (02) : 577 - 586
  • [36] Structure-Activity Relationships Comparing N-(6-Methylpyridin-yl)-Substituted Aryl Amides to 2-Methyl-6-(substituted-arylethynyl)pyridines or 2-Methyl-4-(substituted-arylethynyl)thiazoles as Novel Metabotropic Glutamate Receptor Subtype 5 Antagonists
    Kulkarni, Santosh S.
    Zou, Mu-Fa
    Cao, Jianjing
    Deschamps, Jeffrey R.
    Rodriguez, Alice L.
    Conn, P. Jeffrey
    Newman, Amy Hauck
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (11) : 3563 - 3575
  • [37] Structure activity relationships (SAR) of 3-chloro-3′-((2-cyclopentyl-3-oxo-2,3-dihydrobenzo[d]isothiazol-6-yloxy) methyl)biphenyl-4-carboxylic acid analogs that are metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulators
    Raveendra-Panickar, Dhanya
    Sheffler, Douglas
    Nickols, Hilary Highfield
    D'Souza, Manoranjan
    Yang, Li
    Dahl, Russell
    Semenova, Svetlana
    Markou, Athina
    Conn, Jeffrey
    Cosford, Nicholas D. P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [38] METABOLITE STUDY OF 2-[11C]METHYL-6-(2-PHENYLETHYNYL)PYRIDINE, 2-(2-(3-[11C]METHOXYPHENYL)ETHYNYL)-6-METHYLPYRIDINE, AND 2-(2-(5-[11C]METHOXYPYRIDIN-3-YL)ETHYNYL)PYRIDINE, POTENTIAL PET LIGANDS FOR METABOTROPIC GLUTAMATE SUBTYPE 5 RECEPTORS
    Yu, M.
    Wang, X.
    Zhu, A.
    Brownell, A. -L.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2005, 48 : S332 - S332
  • [39] Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents
    Hikichi, Hirohiko
    Murai, Takeshi
    Okuda, Shoki
    Maehara, Shunsuke
    Satow, Akio
    Ise, Satoko
    Nishino, Miho
    Suzuki, Gentaroh
    Takehana, Hiroshi
    Hata, Mikiko
    Ohta, Hisashi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 639 (1-3) : 106 - 114
  • [40] Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator
    Zhang, Lei
    Balan, Gayatri
    Barreiro, Gabriela
    Boscoe, Brian P.
    Chenard, Lois K.
    Cianfrogna, Julie
    Claffey, Michelle M.
    Chen, Laigao
    Coffman, Karen J.
    Drozda, Susan E.
    Dunetz, Joshua R.
    Fonseca, Kari R.
    Galatsis, Paul
    Grimwood, Sarah
    Lazzaro, John T.
    Mancuso, Jessica Y.
    Miller, Emily L.
    Reese, Matthew R.
    Rogers, Bruce N.
    Sakurada, Isao
    Skaddan, Marc
    Smith, Deborah L.
    Stepan, Antonia F.
    Trapa, Patrick
    Tuttle, Jamison B.
    Verhoest, Patrick R.
    Walker, Daniel P.
    Wright, Ann S.
    Zaleska, Margaret M.
    Zasadny, Kenneth
    Shaffer, Christopher L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (03) : 861 - 877